연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
2037. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ, Min A, Im SA, Jang H, Lee KH, Lau A, Lee M, Kim S, Yang Y, Kim J, Kim TY, Oh DY, Brown J, O`Connor MJ, Bang YJ
Int J Cancer. 2017 Jan 1;140(1):109-119
Link
2036. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Park YH, Im SA, Kim SB, Sohn JH, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim JY, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH; Korean Cancer Study Group (KCSG)
Eur J Cancer. 2017 Nov;86:385-393
Link
2035. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
Min A, Im SA, Jang H, Kim S, Lee M, Kim DK, Yang Y, Kim HJ, Lee KH, Kim JW, Kim TY, Oh DY, Brown J, Lau A, O`Connor MJ, Bang YJ
Mol Cancer Ther. 2017 Apr;16(4):566-577
Link
2034. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
Lee DW, Im SA, Kim YJ, Yang Y, Rhee J, Na II, Lee KH, Kim TY, Han SW, Choi IS, Oh DY, Kim JH, Kim TY, Bang YJ
Cancer Res Treat. 2017 Jul;49(3):807-815
Link
2033. Korean Cancer Patients` Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate.
Lim Y, Lim JM, Jeong WJ, Lee KH, Keam B, Kim TY, Kim TM, Han SW, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Im SA
Cancer Res Treat. 2017 Oct;49(4):1033-1043
Link
2032. Effect and Mechanisms of Diabetes Resolution According to the Range of Gastric Resection and the Length of Anastomosis in Animal Models: Implication for Gastric Cancer Surgery in Patients with Diabetes Mellitus.
Huh YJ, Son YG, Kim TH, Park JH, Oh TJ, Choi B, Min J, Cho YM, Yang HK, Lee HJ (corresponding author).
World J Surg 2017 Sep 19 [Epub ahead of print]
Link
2031. Plasma expression of the intestinal metaplasia markers CDH17 and TFF3 in patients with gastric cancer.
Choi B, Lee HJ (corresponding author), Min J, Choe HN, Choi YS, Son YG, Ahn HS, Suh YS, Goldenring JR, Yang HK.
Cancer Biomark 2017 Jul 4;19(3):231-239.
Link
2030. Postoperative oral nutritional supplementation after major gastrointestinal surgery: a randomized controlled clinical trial.
Kong SH, Park JS, Lee IK, Ryu SW, Park YK, Yang HK, Han SU, Yoon KY, Jeong SY, Jeong MR, Hwang DW, Suh YS, Yoon YS, Seo KW, Park JW, Byun CS, Hur H, Won H, Choi Y, Lee HJ (corresponding author).
Asia Pac J Clin Nutr 2017;26(5):811-819.
Link
2029. Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD)
Kim HY, Yoo TH, Hwang Y, Lee GH, Kim B, Jang J, Yu HT, Kim MC, Cho JY, Lee CJ, Kim HC, Park S, Lee WW.
Sci Rep. 2017 Jun 8;7(1):3057.
Link
2028. Upregulation of SLC2 (GLUT) family genes is related to poor survival outcomes in papillary thyroid carcinoma: Analysis of data from The Cancer Genome Atlas.
Chai YJ, Yi JW, Oh SW, Kim YA, Yi KH, Kim JH, Lee KE
Surgery. 2017 Jan;161(1):188-194. doi: 10.1016/j.surg.2016.04.050. Epub 2016 Nov 11.
Link